CLASS III Drug recall · Reported 6 Dec 2017 · FDA Enforcement Report

Duloxetine Delayed-Release Capsules USP, 30 mg recalled

Lupin Pharmaceuticals is recalling Duloxetine Delayed-Release Capsules USP, 30 mg, distributed nationwide in the US. The recall was initiated on 21 Nov 2017 and the FDA has classified it as Class III.

Check your package

Lot, batch or date codesLot #: G602051, Exp. 12/2017
NDC68180-294, 68180-295, 68180-296, 68180-297
UPC0368180294030, 0368180296034, 368180295068
Quantity recalled111,648 units

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-0097-2018
FDA event ID
78596
Recalling firm
Lupin Pharmaceuticals, Baltimore, MD
Manufacturer
Lupin Pharmaceuticals, Inc.
Classification
Class III
Status
Terminated
Recall initiated
21 Nov 2017
FDA classified
28 Nov 2017
Reported
6 Dec 2017
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay
Drug class
Antidepressants

Timeline

21 Nov 2017Recall initiated by company
28 Nov 2017Classified by FDA+7 days
6 Dec 2017Published in enforcement report+8 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Failed Dissolution Specification

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Goa 403 722 India, NDC 68180-295-06, UPC 368180295068

Where it was distributed

Nationwide within the United States

Nationwide

Questions about this recall

Is Duloxetine Delayed-Release Capsules USP, 30 mg recalled?

Yes. Lupin Pharmaceuticals recalled Duloxetine Delayed-Release Capsules USP, 30 mg on 21 Nov 2017. The recall is Class III and its status is Terminated. Recall number D-0097-2018.

Why was it recalled?

Failed Dissolution Specification

Which lots are affected?

Lot #: G602051, Exp. 12/2017

Where was it sold?

Nationwide within the United States

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class III mean?

Class III recalls are for products unlikely to cause any adverse health consequence, usually labelling or quality issues.

Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Lupin Pharmaceuticals

All 123
ReportedClassRecallCompanyReasonWhere
DrugCLASS IIClobetasol Propionate Cream USP, 05% tube recalledClobetasol PropionateLupin PharmaceuticalsOtherNationwide
DrugCLASS IIprednisoLONE Acetate Ophthalmic Suspension recalledPrednisolone AcetateLupin PharmaceuticalsSterilityNationwide
DrugCLASS IIGlucagon Emergency Kit for Low Blood Sugar, Glucagon recalledGlucagonLupin PharmaceuticalsPotency & AssayNationwide
DrugCLASS IILiraglutide Injection, 18 mg/ (6 mg/mL) recalledLiraglutideLupin PharmaceuticalsParticulate MatterNationwide
DrugCLASS IISertraline Hydrochloride Tablets USP, 100 mg recalledSertraline HydrochlorideLupin PharmaceuticalsPackaging DefectsNationwide

Other Duloxetine recalls

All 55